Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 18/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 18/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 18/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1924855 | 0.83 | CHRM2 (0.74) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL5011192 | 0.81 | CHRM2 (0.74) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL5011190 | 0.81 | CHRM2 (0.74) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL5011049 | 0.80 | CHRM2 (0.72) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL5011058 | 0.80 | CHRM2 (0.72) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL5006127 | 0.80 | CHRM1 (0.61) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL5006125 | 0.80 | CHRM1 (0.61) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL19856550 | 0.79 | CHRM2 (0.64) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL5003527 | 0.79 | CHRM2 (0.75) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| Iodide SCHEMBL4095032 | 0.79 | CHRM2 (0.48) | CHRM2CHRM1CHRM3CHRM5CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060094751-A1 | Quinuclidine derivatives and pharmaceutical compositions containing the same | ALMIRALL, S.A. (ES) | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094751-A1 | Quinuclidine derivatives and pharmaceutical compositions containing the same | CHRM3, CHRM2, CHRM1 | CHRM2 2/4885CHRM1 3/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.